Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Unknown 2

Sponsor Class

OTHER 15INDUSTRY 6NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × NIH × Bexarotene × Clear all
NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT00003752 2013-05-30

Bexarotene in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
180 enrolled
Breast

Breast Neoplasms

NCT00030849 2013-04-04

Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡